Nearly half a million people are diagnosed and treated for Lyme disease in the U.S. every year, and Pennsylvania is a hot bed ...
30m
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial
Oric Pharmaceuticals (NASDAQ:ORIC) detailed new dose-optimization results for its PRC2 inhibitor rinzimetostat and outlined plans to begin its first phase III registrational study in metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results